We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+14.38%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$347M
AUM Growth
-$92.7M
(-21%)
Cap. Flow
-$125M
Cap. Flow
% of AUM
-36.15%
Top 10 Holdings %
Top 10 Hldgs %
71.88%
Holding
54
New
11
Increased
5
Reduced
19
Closed
15
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$9.29M |
| 2 |
Agilent Technologies
A
|
+$5.96M |
| 3 |
Icon
ICLR
|
+$5.89M |
| 4 |
Centene
CNC
|
+$4.47M |
| 5 |
Repligen
RGEN
|
+$4.23M |
Top Sells
| 1 |
Dianthus Therapeutics
DNTH
|
+$42.6M |
| 2 |
Natera
NTRA
|
+$12.2M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$11.6M |
| 4 |
Danaher
DHR
|
+$8.29M |
| 5 |
Medtronic
MDT
|
+$8.06M |
Sector Composition
| 1 | Healthcare | 98.84% |
| 2 | Consumer Staples | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Dianthus Therapeutics
DNTH
$5.46B
| $86.7M | 25.01% |
2,104,184
-1,100,000
| -34% | -$42.6M |
|
2
CG Oncology
CGON
$6.44B
| $61.1M | 17.64% |
1,472,699
-128,200
| -8% | -$5.31M |
|
|
JBIO
3
Jade Biosciences
JBIO
$1.33B
| $21.6M | 6.23% |
1,400,708
+273,522
| +24% | +$3.21M |
|
|
ORKA
4
Oruka Therapeutics
ORKA
$5.23B
| $20M | 5.77% |
660,424
| – | – |
|
5
Teva Pharmaceuticals
TEVA
$36.7B
| $13M | 3.76% |
417,300
-92,700
| -18% | -$2.28M |
|
6
Boston Scientific
BSX
$64B
| $10.9M | 3.15% |
114,500
-49,800
| -30% | -$4.88M |
|
|
7
Medtronic
MDT
$103B
| $10.3M | 2.98% |
107,600
-83,000
| -44% | -$8.06M |
|
8
Perspective Therapeutics
CATX
$367M
| $8.83M | 2.55% |
3,210,733
+216,700
| +7% | +$618K |
|
|
9
Alnylam Pharmaceuticals
ALNY
$37.3B
| $8.35M | 2.41% |
+21,000
| New | +$9.29M |
|
|
10
Repligen
RGEN
$8.35B
| $8.24M | 2.38% |
50,300
+27,000
| +116% | +$4.23M |
|
11
Context Therapeutics
CNTX
$57.9M
| $8.09M | 2.33% |
5,504,855
-3,477,000
| -39% | -$4.06M |
|
12
McKesson
MCK
$93.2B
| $7.81M | 2.25% |
9,520
+3,720
| +64% | +$3.04M |
|
|
13
Icon
ICLR
$13.3B
| $6.03M | 1.74% |
+33,100
| New | +$5.89M |
|
|
14
Agilent Technologies
A
$38B
| $5.65M | 1.63% |
+41,500
| New | +$5.96M |
|
15
Pfizer
PFE
$141B
| $5.07M | 1.46% |
203,600
-162,800
| -44% | -$4.11M |
|
|
16
Centene
CNC
$32.9B
| $4.91M | 1.42% |
+119,400
| New | +$4.47M |
|
17
Kenvue
KVUE
$35.9B
| $4.02M | 1.16% |
232,800
-32,400
| -12% | -$530K |
|
|
18
Danaher
DHR
$142B
| $3.89M | 1.12% |
17,000
-37,700
| -69% | -$8.29M |
|
19
Thermo Fisher Scientific
TMO
$199B
| $3.88M | 1.12% |
6,700
-12,200
| -65% | -$6.9M |
|
|
NVO
20
Novo Nordisk
NVO
$224B
| $3.42M | 0.99% |
+67,300
| New | +$3.44M |
|
21
Phathom Pharmaceuticals
PHAT
$881M
| $3.42M | 0.99% |
206,076
-99,924
| -33% | -$1.43M |
|
22
Encompass Health
EHC
$10.9B
| $3.35M | 0.97% |
31,600
-10,300
| -25% | -$1.19M |
|
23
Cigna
CI
$78.8B
| $3.19M | 0.92% |
11,600
-5,000
| -30% | -$1.4M |
|
24
Cencora
COR
$57.7B
| $3.17M | 0.92% |
9,400
-9,600
| -51% | -$3.27M |
|
25
Insmed
INSM
$23.8B
| $3.08M | 0.89% |
17,700
+6,100
| +53% | +$1.11M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH